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Dual role of the p38 MAPK/cPLA2 pathway in the
regulation of platelet apoptosis induced by ABT-737
and strong platelet agonists
N Rukoyatkina1,2, I Mindukshev2, U Walter3 and S Gambaryan*,1,2
p38 Mitogen-activated protein (MAP) kinase is involved in the apoptosis of nucleated cells. Although platelets are anucleated
cells, apoptotic proteins have been shown to regulate platelet lifespan. However, the involvement of p38 MAP kinase in platelet
apoptosis is not yet clearly defined. Therefore, we investigated the role of p38 MAP kinase in apoptosis induced by a mimetic of
BH3-only proteins, ABT-737, and in apoptosis-like events induced by such strong platelet agonists as thrombin in combination
with convulxin (Thr/Cvx), both of which result in p38 MAP kinase phosphorylation and activation. A p38 inhibitor (SB202190)
inhibited the apoptotic events induced by ABT-737 but did not influence those induced by Thr/Cvx. The inhibitor also reduced the
phosphorylation of cytosolic phospholipase A2 (cPLA2), an established p38 substrate, induced by ABT-737 or Thr/Cvx. ABT-737,
but not Thr/Cvx, induced the caspase 3-dependent cleavage and inactivation of cPLA2. Thus, p38 MAPK promotes ABT-737-
induced apoptosis by inhibiting the cPLA2/arachidonate pathway. We also show that arachidonic acid (AA) itself and in
combination with Thr/Cvx or ABT-737 at low concentrations prevented apoptotic events, whereas at high concentrations it
enhanced such events. Our data support the hypothesis that the p38 MAPK-triggered arachidonate pathway serves as a defense
mechanism against apoptosis under physiological conditions.
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Platelets play a key role in normal and pathological
hemostasis through their ability to rapidly adhere to activated
or injured endothelium and subendothelial matrix proteins
(platelet adhesion), and to other activated platelets (platelet
aggregation).1 Platelets are also considered as key mediators
of thrombosis, vascular inflammation, and atherosclerosis.2,3
Apoptosis play a significant role in platelet production from
megakaryocytes, and circulating platelets contain many
components of the apoptotic machinery.4 Indeed, cytochrome
c, caspase 9, caspase 3, apoptotic protease-activating factor,
and Bcl-2 family proteins (for example, BAK, BAX, Bcl-XL, Bcl-
2, Bclw, Bim, Bid) are all expressed in platelets.
5–8
A variety of stimuli can induce apoptotic or apoptotic-like
events in platelets, such as ABT-737, thrombin, collagen, and
A23187. ABT-737, a potent mimetic of Bcl-2 homology BH3-
only proteins (including Bim, Bid, and other proteins that can
be important for binding and neutralizing antiapoptotic Bcl-2
family proteins), induces caspase-dependent platelet apop-
tosis that is associated with BAX translocation from the
cytosol to mitochondria and homo-oligomerization.7 In highly
activated platelets, several structural and functional changes,
such as phosphatidylserine (PS) externalization, cell shrink-
age, loss of mitochondrial membrane potential (DCm),
microparticle (MP) formation, and cleavage of gelsolin and
protein kinase C-d, are reminiscent of nucleated cell
apoptosis.9–13 However, strong agonists either did not
activate caspase 314 or did so very weakly.15–17 A total
of 13 types of cell death have been characterized for
nucleated cells, including caspase-dependent and caspase-
independent intrinsic apoptosis, autophagic cell death,
necroptosis and others.18 Although highly activated platelets
exhibit the characteristic features of dying cells, there is no
consensus in the literature clearly defining the type of strong
activated platelet death. Some authors define them as
necrotic cells19 whereas others11,20,21 consider them as
apoptotic platelets.
Mitogen-activated protein (MAP) kinases represent a family
of threonine/tyrosine-activated serine/threonine kinases that
control many cellular responses, such as proliferation,
migration, differentiation, and apoptosis. In platelets, p38
MAP kinase is phosphorylated and activated by different
physiological agonists, including thrombin, collagen, and
thromboxane A2 (TxA2).
22–25 However, the mechanisms of
p38 activation and their downstream effects are controversial
and have not been clearly defined. p38 has been suggested to
regulate platelet adhesion to collagen26 and aggregation.24,27
In contrast, using different p38 inhibitors, other authors did not
find any significant effect of p38 on platelet activation.28–31
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One of the established p38 substrates in platelets is
cytosolic phospholipase A2 (cPLA2), which is phosphorylated
by p38 at serine505 in agonist-stimulated platelets.32–34
In platelets, cPLA2 activity is responsible for the release of
arachidonic acid (AA) from membrane phospholipids.35 AA is
thenmetabolized by cyclooxygenase to prostaglandins, which
are further converted to TxA2 by thromboxane synthase
(TxS). In addition, AA is involved in the regulation of reactive
oxygen species (ROS) production. cPLA2-induced AA is a
prominent requirement for the activation of NADPH oxidase
and generation of ROS in phagocytes.36 ROS may also be
generated as a by-product during the oxidation of AA by
cyclooxygenase or lipoxygenase.37,38 Therefore, platelet
cPLA2 is involved in the regulation of two different functions,
ROS generation and eicosanoid production. Excess ROS
generation and AA release play essential roles in the initiation
of apoptosis in platelets.21,39 As p38/cPLA2 is involved in the
regulation of nucleated cell apoptosis40–43 and the possible
involvement of p38/cPLA2 in the induction of platelet apoptotic
events is not known, we compared the mechanism of p38/
cPLA2-mediated signaling induced by platelet agonists and
ABT-737.
In this study, we show that p38 plays a significant role in
ABT-737-induced platelet apoptosis, whereas it has no effect
on thrombin in combination with convulxin(Thr/Cvx)-induced
apoptotic-like events. ABT-737, but not Thr/Cvx, induced the
caspase-dependent cleavage and inactivation of cPLA2.
We also assessed multiple influences of AA/ROS on
apoptotic-like events in platelets and suggest that the p38-
triggered arachidonate pathway serves as a defensemechan-
ism under physiological conditions.
Results
Activation of p38 MAP kinase plays a significant role in
ABT-737-induced platelet apoptosis. To clarify the func-
tion of p38 in platelet apoptosis induced by two independent
pathways, the BH3 mimetic compound ABT-737 was used as
an activator of the BAK/BAX-caspase pathway and a
combination of Thr/Cvx as agonists of the second caspase-
independent pathway.
In our study, we used terms apoptosis-like events for
platelets activated by strong agonists and apoptosis for ABT-
737-induced platelet death. ABT-737 at concentrations
ranging from 0.1 to 1 mM induced dose- and time-dependent
increases in Annexin V binding (Figures 1a and c). Simulta-
neously, ABT-737 (0.1–1 mM) time dependently increased the
phosphorylation of p38 (Figure 1b). In contrast to Thr/Cvx,
ABT-737 did not activate aIIbb3 integrins (Figure 1c) and did
not induce MP formation (Figures 6a and b). The activation of
p38 by thrombin and convulxin alone or in combination (Thr/
Cvx) was transient, reaching a maximum after 5min of
incubation and then gradually decreasing to a level compar-
able with that of the control after 60min (Figure 1d).
Conversely, activation of p38 by ABT-373 was detectable
only after 20min of stimulation and remained constant even
up to 90min of stimulation (Figure 1a). A p38 inhibitor
(SB202190, 1mM) significantly decreased the amount of
Annexin V-positive platelets (67±3% compared with
ABT-737-stimulated platelets taken as 100%) and prevented
decreases in DCm (32±4%) stimulated by ABT-737 (Figures
2a and b). Similarly, SB202190 inhibited the cleavage of
procaspase 3 by 31±3% (Figures 2 c and d), indicating that
p38 is partly involved in ABT-737-induced caspase 3
activation and apoptosis.
p38 MAP kinase is not involved in the generation of
apoptotic-like events triggered by Thr/Cvx. We next
investigated whether the activation of p38 is involved in
Thr/Cvx-induced platelet death. The activation of platelets by
Thr/Cvx significantly increased Annexin V binding 7.6±1.5
Figure 1 BH3 mimetic (ABT-737) phosphorylates p38. (a) FACS analysis of
Annexin V binding and (c) PAC-1 binding (integrin aIIbb3 activation, mean
fluorescence, AU) to WP (1 107/ml) incubated with ABT-737. Annexin V and
PAC-1 binding are presented as the fold increase compared with the control taken
as 1. Data are presented as means±S.E.M, n¼ 5; þ Po0.05 compared with the
control. (b and d) Western blot analysis using WP (4 108/ml) of p38
phosphorylation after incubation with thrombin (5 mU/ml) and convulxin (5 ng/ml)
or ABT-737 (0.1–1 mM) (data shown are representative of three independent
experiments)
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compared with control 1±0.14) and aIIbb3 integrin activation
(Figure 3a). The inhibition of p38 (SB202190, 1 mM), as
assessed by the phosphorylation of its established substrate
(HSP27) (Figures 3c and d), did not significantly inhibit
Annexin V binding (Figure 3a) or decreases in DCm
(Figure 3b) and had no effect on aIIbb3 integrin activation
(Figure 3a), indicating that p38 is not involved in Thr/Cvx-
induced platelet apoptotic-like events.
Platelet cPLA2 cleavage by ABT-737 is caspase depen-
dent. The stimulation of platelets by Cvx and Thr/Cvx (both
5min) and by ABT-737 (30min) induced p38 and cPLA2
phosphorylation, and the latter was partly (in the case of Cvx
and Thr/Cvx) and fully (in the case of ABT-737) prevented by
preincubation with SB202190 (Figures 4a and b). However,
in contrast to Cvx and Thr/Cvx, ABT-737 induced the
cleavage of cPLA2, which was prevented by a procaspase
3 inhibitor (z-DEVD-fmk) at concentrations of 50–100 mM
(Figures 4c and d). We then tested whether the cleavage of
cPLA2 would inhibit its activity. One of the main functions of
cPLA2 in platelets is associated with the production of
thromboxane (TxA2) TxS. ABT-737 (1mM) induced only a
weak activation of TxS (4±0.3-fold increase compared with
the control taken as 1), Cvx and Thr/Cvx (Figure 4e) strongly
activated TxS (20±1.3- and 52±1.3-fold, respectively). The
inhibition of p38 (SB202190, 1mM) decreased the TxS
activity induced by Cvx or Thr/Cvx to 75±1.7% and
87±1.8%, respectively, compared with the agonist-induced
activity taken as 100% (Figure 4f).
Arachidonic acid prevents apoptosis in platelets at low
concentrations and induces apoptosis in platelets at
high concentrations. In nucleated cells, AA has been
shown to contribute to mitochondrial dysfunction during
apoptosis;44,45 however, AA was used at very high concen-
trations (more than 10 mM) in these studies. The depletion of
AA prevents apoptotic development in cold-stored platelets
whereas incubation with extremely high concentrations of AA
(50–100 mM) induces platelet apoptosis.39 In the present
study, we tested whether AA would contribute to apoptosis in
freshly isolated platelets. Washed platelets (WP) were
incubated with different concentrations of AA (10 7 to
10 4 M), and apoptosis was assessed by decreases in
DCm, PS exposure, and procaspase 3 cleavage. At high
concentrations (10 5 and 10 4 M), AA did indeed induce a
decline in DCm (Figure 5a) and an increase in Annexin V
binding (Figure 5b) and cleavage of procaspase 3 after 24 h
of incubation (Figure 5c). However, at low concentrations
(10 6 and 10 7 M), AA appeared to have antiapoptotic
effects: it did not affect Annexin V binding, slightly increased
Figure 2 p38 MAP kinase inhibition prevents ABT-737-induced platelet
apoptosis (a) FACS analysis of Annexin V-positive platelets (1 107/ml) and
(b) mitochondrial membrane potential (DCm) in WP incubated with ABT-737
(0.1mM, 30 min) or pretreated (10 min, 1 mM) with p38 inhibitor (SB202190). (c)
Western blot and (d) densitometry analyses of caspase 3 in human WP (4 108/ml)
incubated with ABT-737 (0.1mM) or pretreated (10 min, 1 mM) with p38 inhibitor
(SB202190). In (a), ABT-737 was taken as 100%; in (b) and (d), the control was
taken as 100%. Data are presented as means±S.E.M, n¼ 4; þPo0.05
compared with the control, *Po0.05 compared with ABT-737
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DCm (Figure 5a), and decreased the procaspase 3 cleavage
(Figures 5d and e) induced by ABT-737 and procaspase 3
cleavage in stored platelets after 24 h (Figure 5c). At low
concentrations, AA also decreased the Annexin V binding
induced by Thr/Cvx and ABT-737. In accordance with these
data, AA induced MP formation only at high concentrations
(Figures 6a and b).
ROS generated by activated platelets are not directly
correlated with apoptotic events. AA can be involved in
the regulation of ROS production as a by-product during the
oxidation of AA by cyclooxygenase or lipoxygenase.37
In addition, AA can directly activate NADPH oxidase, inducing
ROS generation.46 As MP formation in platelets may be
induced by ROS,47,48 we compared MP formation and ROS
production in platelets activated by ABT-737 (1 mM),
AA (10 6 and 10 4 M), and Thr/Cvx (5mU/5 ng/ml). AA at
a concentration of 10 4 M induced the highest amount of
MPs (2.7±0.34 fold compared with the control taken as 1),
and Thr/Cvx induced 1.7±0.2; neither a low concentration of
AA (10 6 M) nor 1 mM ABT-737 induced significant MP
formation (Figures 6a and b).
ROS production was strongly induced by AA at a low but not
at a high concentration (27±5.6 and 3±1.5-fold respectively,
compared with the control taken as 1) (Figure 6c). Thr/Cvx
stimulation also significantly increased ROS production
(20±4-fold, compared with the control taken as 1), whereas
ABT-737 had no effect on platelet ROS production
(Figure 6c).
Discussion
In nucleated cells, stress-activated p38 MAPK is involved in
apoptosis, cytokine production, cytoskeleton reorganization,
and transcriptional regulation. p38MAPK also appears to play
a role in the pathogenesis of heart ischemia, sepsis, arthritis,
Figure 3 p38 inhibitor does not prevent PS surface exposure, decreased DCm, and integrin aIIbb3 activation in platelets stimulated with Thr/Cvx (a) FACS analysis of
Annexin V-positive cells and PAC-1 binding and (b)DCm in WP (1 107/ml) stimulated by Thr/Cvx or pretreated (10 min, 1 mM) with p38 inhibitor (SB202190). In (a) and (d),
Thr/Cvx was taken as 100%; in (b), control was taken as 100%. Data are presented as means±S.E.M, n¼ 6; þ Po0.05 compared with the control, *Po0.05 compared
with platelets incubated with Thr/Cvx. (c) Western blot and (d) densitometry analyses of p38 and HSP27 phosphorylation in WP (3 108/ml) stimulated with Thr/Cvx or
pretreated (10 min, 1mM) with p38 inhibitor (SB202190). The data shown are representative of three independent experiments
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human immunodeficiency virus infection, and Alzheimer’s
disease.49 In platelets, p38 MAPK has been shown to be
activated by almost all platelet agonists, including thrombin,
collagen, ADP, and TxA2.
22–25 Nonetheless, the involvement
of p38 in the mechanisms that trigger apoptosis in platelets
has remained unclear. Therefore, we investigated the func-
tions of p38 in the regulation of apoptosis induced by ABT-737
and the apoptosis-like events induced by strong agonists (Thr/
Cvx). We found that ABT-737 dose- and time-dependently
resulted in the phosphorylation of p38 (Figure 1).
The inhibition of p38 significantly prevented platelet apoptosis,
as assessed by PS-positive cells, a decrease in mitochondrial
potential, and cleavage of caspase 3 (Figure 2). cPLA2 is an
established p38 substrate in platelets,23,32–34 and we show
that the ABT-737-induced activation of p38 triggered cPLA2
phosphorylation. In nucleated cells undergoing apoptosis,
cPLA2 is cleaved and inactivated by caspase 3 activation.
50,51
In platelets, cPLA2 was also cleaved upon ABT-737 activation
and inactivated by a caspase 3-dependent mechanism
(Figures 4a and b). In contrast, Thr/Cvx treatment induced
the phosphorylation of cPLA2 but did not promote its
degradation (Figure 4a). Consistent with these data,
Thr/Cvx strongly enhanced cPLA2 activity compared with
the effect of ABT-737 (Figure 4e). It is important to note that
the inhibition of p38 significantly prevented the apoptosis
induced by ABT-737 but had no effect on the apoptotic-like
events triggered by Thr/Cvx stimulation (Figure 3). As ABT-
737-induced platelet apoptosis was directly correlated with
the cleavage and inactivation of cPLA2 and because Thr/Cvx
stimulation strongly activated cPLA2, which was responsible
for AA generation, we tested whether AA itself was involved in
apoptosis. In nucleated cells, high concentrations of AA
contribute to mitochondrial dysfunction and apoptotic cell
death,44,45,52 and AA also promotes apoptosis in stored
platelets.39 In addition, the concentration of AA can increase
up to 10-fold during cerebral or heart ischemia compared with
normal physiological conditions.53,54 Therefore, we tested the
effects of different AA concentrations on hallmarks of platelet
apoptosis. AA at low concentrations (10 7–10 6 M)
enhanced DCm, but had no influence on PS externalization
and did not cleave caspase 3. In contrast, AA at high
concentrations (10 5–10 4 M) induced a decrease in DCm,
enhanced PS externalization, and activated caspase 3
(Figure 5). Thus, the amount of AA might be an essential
Figure 4 ABT-737 cleavage of platelet cPLA2 is caspase dependent. (a) Western blot and (b) densitometry analysis of p-cPLA2 in WP incubated with Cvx (5 ng/ml),
Thr/Cvx (5 mU/5 ng/ml), or ABT-737 (1 mM) or pretreated (10 min, 1 mM) with p38 inhibitor (SB202190). (c) Western blot and (d) densitometry analysis of cPLA2 in WP after
stimulation with ABT-737 or pretreated with the indicated concentrations of the caspase 3 inhibitor:z-DEVD. Western blot data are representative of three independent
experiments of p38 and cPLA2 phosphorylation in WP (4 108/ml). (e and f) ELISA data for the TxS activity in WP (4 108/ml) activated by Cvx (5 ng/ml, 5 min), Thr/Cvx
(5 mU/5 ng/ml, 5 min), or ABT-737 (1mM, 30 min) and after preincubation with SB202190 (1mM, 10 min)
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Figure 5 Arachidonic acid at low concentrations prevents, and at high concentrations induces apoptosis in platelets. (a) FACS analysis ofDCm and (b) Annexin V binding
in WP (1 107/ml) stimulated with AA for 5 min at the indicated concentrations. (f) Inhibition of Annexin V binding by AA (10 7–10 6 M) in platelets stimulated with Thr/Cvx
(5 min) and ABT-737 (1 mM, 30 min). (c and d) Western blot analysis (data shown are representative of three independent experiments) of caspase 3 in WP (4 108/ml) after
stimulation with AA at the indicated concentrations for 2 and 24 h (c) and after stimulation with ABT-737 alone and in combination with AA for 30 min (d) and (e) densitometry
analysis of (d). In (e), the control was taken as 100%. Data are presented as means±S.E.M, n¼ 6; þPo0.05 compared with the control, *Po0.05 compared with platelets
incubated with ABT-737
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factor for mediating pro or antiapoptotic-like effects in
platelets. We next addressed whether different concentra-
tions of AA could prevent or enhance the apoptotic events
induced by Thr/Cvx and ABT-737. Accordingly, we found that
AA at low concentrations (10 7 for Thr/Cvx and 10 6 for
ABT-737) inhibited the apoptotic events induced by both
stimuli (Figure 5). The higher concentrations of AA required
for the inhibitory effects of ABT-737-induced apoptosis were
most likely associated with the inactivation of cPLA2 and
consequently a reduced basal AA concentration in this case.
ROS are involved in cellular responses to stress55 and may
contribute to various cellular pathological events, including
apoptosis56 and, in particular, MP formation.47,48 We inves-
tigated whether MP formation induced by ABT-737, Thr/Cvx,
and AA correlates with ROS production and found increases
only in the Thr/Cvx- and 10 6 M AA-treated platelets
(Figure 6c), whereas MPs were enhanced only in the Thr/
Cvx- and 10 4 M AA-stimulated platelets (Figures 6a and b),
indicating that ROS are most likely not directly linked to
apoptotic events.
In summary, we show here that p38 MAP kinase plays a
significant role in platelet apoptosis induced by ABT-737, but
is not involved in the generation of the apoptotic-like events
triggered by physiological stimuli (Thr/Cvx). Consistently,
under physiological conditions, the p38-triggered activation of
cPLA2, release of AA, and ROS generation may serve as
mechanisms to protect cells from apoptosis. In contrast, a
high concentration of AA (as often observed under patholo-
gical conditions) may promote proapoptotic events.
Materials and Methods
Materials. Thrombin was obtained from Roche (Mannheim, Germany), and
convulxin (Cvx) (ligand of glycoprotein VI from the snake venom Crotalus durissus
terrificus) was purchased from LOXO (Dossenheim, Germany). SB202190 and
z-DEVD-fmk were purchased from Calbiochem (Schwalbach, Germany), and ABT-
737 was provided by Selleck Chemicals (Munich, Germany). Antibodies against
p38, phospho-p38, and actin were obtained from Sigma (Munich, Germany).
Antibodies against phospho-HSP27, phospho-cPLA2, cPLA2, and caspase 3 were
from Cell Signaling (Frankfurt, Germany). Anti-rabbit and anti-mouse IgG
conjugated with horseradish peroxidase were obtained from Amersham,
Pharmacia Biotech (Freiburg, Germany). The fluorescent dyes Annexin-V-PE
and PAC-1 were obtained from BD-Bioscience (Heidelberg, Germany). JC1 was
obtained from Invitrogen (Eugen, Germany), and H2DCF-DA was purchased from
Molecular Probes (Go¨ttingen, Germany).
Platelet preparation. Human platelets were prepared and used as
previously reported,57 with minor modifications. Blood was obtained from healthy
volunteers according to our institutional guidelines and the Declaration of Helsinki.
Our studies with human platelets were approved and recently (24 September,
2008) reconfirmed by the local ethics committee of the University of Wu¨rzburg
(Studies Number 67/92 and 114/04).
Blood was collected into 1/7 volume of ACD solution (12 mM citric acid, 15 mM
sodium citrate, 25 mM D-glucose, and 2 mM EGTA, final concentrations). Platelet
rich plasma was obtained by a 5-min centrifugation at 330 g. To reduce leukocyte
contamination, Platelet rich plasma was diluted 1 : 1 with PBS and centrifuged at
240 g for 10 min. The supernatant was centrifuged for 10 min at 430 g, and the
pelleted platelets were washed once in CGS buffer (120 mM sodium chloride,
12.9 mM trisodium citrate, and 30 mM D-glucose, pH 6.5) and resuspended in
HEPES buffer (150 mM sodium chloride, 5 mM potassium chloride, 1 mM
magnesium chloride, 10 mM D-glucose, and 10 mM HEPES, pH 7.4) without
stirring; 1 mM CaCl2 was added directly before platelet stimulation.
WP were used at a concentration of 3 108/ml for western blot analysis and TxS
activity, and a concentration of 1 107/ml was used for flow cytometry analysis.
Flow cytometry (FACS) analysis. FACS analysis was performed using a
Becton Dickinson FACS Calibur with CELLQuest software, version 3.1f (Becton
Dickinson, Heidelberg, Germany). For the detection of surface PS or activated aIIbb3
integrins, WP (50ml) were labeled with Annexin V-PE or PAC-1-FITC (both 1 : 10
dilution) for 10 min at RT after agonist stimulation. The platelets were then diluted 10
times with Annexin V-binding solution (140 mM NaCl, 10 mM HEPES, and 2.5 mM
CaCl2) for Annexin V or PBS for PAC-1 and immediately analyzed by flow cytometry.
Analysis of mitochondrial membrane potential. The DCm in human
platelets was analyzed with JC1 dye (1.5mM final concentration). JC1 was
incubated with WP (50 ml) for 10 min at RT, and the samples were diluted (1 : 10)
in PBS and analyzed by FACS. Green fluorescence (FL1) and red fluorescence
(FL2) were measured in logarithmic scales using voltage settings of 710 and 588,
respectively. Compensation settings (FL1-%FL2 and FL2-%FL1) were performed
using FITC and PE beads (BD-Bioscience). JC1 is sensitive to DCm, and the ratio
of fluorescence in FL2 to FL1 corresponds to changes in DCm.
Measurement of ROS production. Intracellular ROS production was
analyzed by H2DCF-DA, as described previously.
58 Briefly, WP were preloaded with
10mM H2DCF-DA for 30 min at 37 1C in HEPES buffer. H2DCF-DA is a cell-
permeable, nonfluorescent dye converted intracellularly to cell-impermeable H2DCF
by intracellular esterases; the dye can then be oxidized by ROS to the fluorescent
species (DCF) that is measured by flow cytometry. After incubation with agonists,
the reaction was stopped by diluting the platelets in PBS for FACS analysis.
Measurement of thromboxane synthase activity. The TxS activity
(TxA2 synthase) was measured as described
59 using a method based on
Figure 6 Microparticle generation and ROS production from platelets activated
by different stimulators. Human WP were stimulated with ABT-737 (1mM, 60 min),
Thr/Cvx (5 mU/5 ng/ml, 2 min), and AA at the indicated concentrations (5 min) and
processed for FACS analysis of MP formation, as assessed by the SSC/FSC plot
(a and b) and (c) ROS production (DCF-DA fluorescence). The MP counts and
DCF-DA fluorescence are presented as a fold increase compared with the control
taken as 1. Data are presented as means±S.E.M, n¼ 4; *Po0.05 compared with
the control. (a) Representative plots (SSC/FSC) of the original data
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malondialdehyde formation by TxA2 synthase. For the experiments, 0.2-ml aliquots
of WP (3 108/ml) were incubated with the reagents at 37 1C with gentle shaking;
the reaction was stopped by the addition of 0.115 ml of ice-cold trichloroacetic acid
(20% wt/vol). The samples were kept on ice for 10 min and then centrifuged for
10 min at 14 000 r.p.m. Equal volumes of thiobarbituric acid (0.53% wt/vol) and
supernatant were combined and incubated for 30 min at 70 1C. The mixture was
then incubated for 30 min at room temperature, and fluorescence was measured
with a Wallac Victor2 1420 Multilabel counter (Perkin Elmer Wallac Life and
Analytical Sciences, Boston, MA, USA) at excitation and emission wavelengths of
520 nM and 550 nM, respectively. Standards were prepared from the stable
malondialdehyde derivate tetraethoxypropane with thiobarbituric acid in the
presence of trichloroacetic acid.
Western blot analysis. For western blot analysis, WP were added directly to
sodium dodecyl sulfate (SDS) gel-loading buffer and analyzed by SDS-
polyacrylamide gel electrophoresis (PAGE), as described.57 The separated
proteins were transferred to a nitrocellulose membrane and incubated with the
primary antibody overnight at 4 1C. For visualization of the signal, goat anti-rabbit
or anti-mouse IgG conjugated with horseradish peroxidase was used as a
secondary antibody, followed by ECL detection (Amersham, Pharmacia Biotech).
Data analysis. All experiments were performed with at least n¼ 4, and the
combined data are expressed as means±S.E.M Differences between groups
were analyzed by ANOVA, followed by Bonferroni´s test; Student’s t-test was used
when appropriate. A value of Po0.05 was considered statistically significant.
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